EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, L.
Right arrow Articles by Jaffe, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, L.
Right arrow Articles by Jaffe, R. B.
Experimental Biology and Medicine 231:1646-1652 (2006)
© 2006 Society for Experimental Biology and Medicine

ORIGINAL RESEARCH ARTICLE

Paracrine VEGF/VE-Cadherin Action on Ovarian Cancer Permeability

Limin Hu*, Napoleone Ferrara{dagger} and Robert B. Jaffe*,1

* Center for Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143-0556; {dagger} Department of Molecular Oncology, Genentech, Inc., South San Francisco, California 94080

To whom requests for reprints should be addressed at 1 Center for Reproductive Sciences, University of California, San Francisco, 505 Parnassus Avenue, HSW 1450, San Francisco, CA 94143-0556. E-mail: jaffer{at}obgyn.ucsf.edu

Ascites formation associated with neoplasms is most likely due to increased vascular permeability, a process in which vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) plays a pivotal role. We hypothesized that tumor-derived VEGF/VPF modulates ascites formation through a paracrine effect on both tumor and peritoneal vessels. We investigated human vascular endothelial permeability using a newly developed dual-chamber permeability assay by co-culturing human umbilical vein cells with and without ovarian cancer cell lines (OVCAR-3, Hey-A8, and OCC-1) in the presence or absence of a human VEGF monoclonal antibody and VE-cadherin function–blocking antibody. This method permits determination of mechanisms by which substances released from neoplasms and other sources of vascular endothelial cell secretagogues modulate vascular permeability and likely other pathologic states.

Key Words: vascular permeability • ovarian cancer • VEGF • VE-cadherin






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society for Experimental Biology and Medicine.